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Abstract - The era of new antipsychotics that started with Clozapine and the ever growing number of newly 
patented drugs have strongly influenced the pattern of drug use and consumption among psychiatric pa-
tients. Authors present a study aiming to assess exclusively the out-of-hospital antipsychotic drug consump-
tion within Albania, during a period covering thirteen years [2004-2016]. Data were obtained from official 
sources [Health Insurance Institute] that registers and eventually reimburses all prescriptions in this field. 
Some outflows from the officially reimbursement scheme has been as well reported, due to circulating (but 
not yet registered) new drugs. A significant trend towards the decrease of consumption of old, typical anti-
psychotics is seen; in favour of new and modern drugs whose side effects profile is obviously a better one. 
Also, Albania has a lower figure of overall out-of-hospital antipsychotic usage when compared with other 
countries. Under-diagnosing and under-treatment might be some of the factors leading to such a fact, to-
gether with accessibility of psychiatric care and society stigma that still deeply impregnate the today Albanian 
society.
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Introduction
Antipsychotics represent a variegate fam-
ily of  active principles, aiming to reduce posi-
tive symptoms of  a psychosis (among other 
hallucinations, agitation and combativeness) 
as well as negative ones (such as social isola-
tion and emotional flatness). Humanity has 
ever since its written history exists, attempted 
to influence thought and behaviour, but an-
cient medicine had at hand exclusively plant 
by-products (opiates, cannabis) that generally 
produced sedation and induced sleep, with-
out modulating the extorted perspective / 
perception of  life, such as encountered dur-
ing psychosis. 
The chance discovery of  chlorproma-
zine in 1951 and the wide usage of  this drug 
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thereafter in a diversity of  psychic disorders 
opened the door of  an ever growing phar-
maceutical research, that gave birth to a new 
generation of  antipsychotics with larger ef-
ficacy, and less side effects [1,2]. The psychi-
atrists obviously started shifting their thera-
peutics from typical to the so-called atypical, 
new and modern antipsychotics in a trend 
that seems universal [3]. 
Studying the trend and characteristics of  
antipsychotic usage in a population will have 
to consider several aspects of  drug avail-
ability, access to psychiatric care and gener-
ally speaking, the overall public health situ-
ation. Denial of  psychiatric issues, related to 
an overinflated ideology, have been common 
to totalitarian regimes [4]. However, history 
differs largely enough to render impossible 
any comparison in between usage of  antipsy-
chotics during certain time frames; not only 
antipsychotics are available only since a few 
decennia, but the consumption is influenced 
from many factors, such as population age-
ing [5,6]. 
The present study aims at describing the 
pattern of  antipsychotic consumption in Al-
bania, in an outpatient population and for a 
period covering thirteen years; similar studies 
performed in neighbouring countries will fa-
cilitate comparisons and possibly the creation 
of  a larger, regional perspective [7,8]. 
Materials and methods 
The study aimed to assess the out-of-hos-
pital antipsychotic drugs use in Albania dur-
ing the period 2004-2016. The data were ob-
tained from the Health Insurance Institute, 
(HII) [9]. All data were collected for the pe-
riod 2004-2016 and analysed. The analysis 
included the total number of  prescriptions 
made and quantities of  drugs used.
The data about the population were ob-
tained from the Institute of  Statistics (IN-
STAT) [10]. The data about the consumption 
of  drugs were expressed as a number of  De-
fined Daily Dose (DDDs)/1000 inhabitants/
day. All drugs were classified by groups of  
Anatomic Therapeutic Chemical Classifica-
tion (ATC).
Data on real consumption  
(import and domestic production)
For all the period under study 2004-2016 
there were collected and analysed data from 
the import and domestic production of  the 
drugs, which represent the real consumption 
of  drugs in the country [11]. It was noted that 
the increase in consumption from one year 
to another was small, e.g. the consumption 
from 2013 to 2016 (i.e. 3 years) was increased 
by only 1.68%. Consequently, in order to 
obtain an updated study, the data of  import 
and domestic consumption were chosen only 
for the last three years, 2014-2016, and those 
were involved in a comparative analysis with 
the equivalent consumption data according 
to HII. In order to minimize the effect of  
variations between consumption and stock 
inventory balances from one year to another, 
it was calculated and put to analysis the an-
nual average value of  the three chosen years 
(on one hand that of  the import and domes-
tic consumption, and on the other hand that 
of  HII).
Presentation of the results and statistical 
elaboration
The statistical elaboration of  the obtained 
results was conducted with the statistical 
package StatsDirect (version 2.7.2.). A de-
scriptive statistic was used to report all data 
on drugs consumption and the results ob-
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tained were displayed in tabular form as well 
as through the histogram method.
Average annual values of  consumption at 
the country level and for each district were 
used as a basis to generate the overviews and 
the graphics that illustrate the trends of  con-
sumption for each class of  drugs during the 
10-years period 2004-2016. The linear regres-
sion model was used to evaluate the trends of  
consumption of  drugs relative to the time. A 
value of  p ≤ 0.05 was considered significant.
In order to asses if  there exists a correla-
tion statistically significant between the level 
of  consumption of  drugs and the level of  
morbidity, the Spearman correlation was ap-
plied (with a significance level of  ≤ 0.05).
Results
The data were expressed as a number of  
defined daily doses per 1000 inhabitants/day 
(DDDs/1000). The consumption of  antipsy-
chotic drugs were 2.19-3.49 DDD/1000 in-
habitants/day respectively during the period 
2004-2016. The most prescribed are the atyp-
ical antipsychotics with values of  0.59-1.79 
DDD/1000 inhabitants/day (2004-2016). 
The new generation drugs included are ris-
peridone, clozapine, and olanzapine. Mean-
while the typical antipsychotics consumption 
was 1.60-1.70 DDD/1000 inhabitants/day.
Psychosis morbidity data indicate that 
there exists a correlation statistically signifi-
cant between number of  cases of  the disease 
and DDD/1000 inhabitants/day of  antipsy-
chotics [p = 0,0014] (Figure 1). For the Atyp-
ical Antipsychotics: p=0,0005; strength (with 
significance level ≤ 0,05) = 97,43%; correla-
tion coefficient statistically significant; for the 
Typical antipsychotics: p=0,9815; strength 
(with significance level ≤ 0,05) = 2,63%; cor-
relation coefficient is not statistically signifi-
cant.
Figure 1. Consumption of  Antipsychotics at national level (DDD/1000 inhabitants/day) versus 
Psychosis morbidity (cases/1000 inhabitants). 
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Figure 3. Annual average value of  consumption of  Typical and Atypical Antipsychotics: consump-
tion based on import (real consumption) versus consumption based on HII. 
Figure 2. Annual average value of  consumption of  Atypical Antipsychotics: consumption based 
on import (real consumption) [*] versus consumption based on HII. 
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Figure 2 represents the comparison im-
port-HII in the consumption of  some atypi-
cal antipsychotics. Around 20-30% of  the 
consumption flows out of  the scheme. For 
clozapine (p = 0,1097; strength (with sig-
nificance level ≤ 0,05) = 35,05%; correla-
tion coefficient is not statistically significant). 
For olanzapine: p = 0,0421; strength (with 
significance level ≤ 0,05) = 53,6%; correla-
tion coefficient is statistically significant. For 
risperidone: p = 0,1618; strength (with sig-
nificance level ≤ 0,05) = 27,62%; correlation 
coefficient is not statistically significant. The 
“Import” item includes the consumption 
based on import data as well as the consump-
tion based on domestic production: this rep-
resents the factual consumption.
Figure 3 represents the comparison in the 
consumption of  typical and atypical Antipsy-
chotics. The consumption is based on im-
port (real consumption) versus consumption 
based on HII. There is an evident difference 
between imports – HII, leading to the con-
clusion that only 40% of  the consumption 
of  antipsychotics is covered by the scheme. 
For the Atypical Antipsychotics (p = 0,1097; 
strength (with significance level ≤ 0,05) = 
35,05%; correlation coefficient is not statisti-
cally significant). for the Typical antipsychot-
ics: p=0,9724; strength (with significance 
level ≤ 0,05) = 2,65%; correlation coefficient 
is not statistically significant). The “Import” 
item includes the consumption based on im-
port data as well as the consumption based 
on domestic production: this represents the 
factual consumption.
Figure 4 represents the consumption of  
typical and atypical antipsychotics in different 
regions and at the national level (DDD/1000 
inhabitants/day). 
Figure 5 represents the international com-
parison in the consumption of  antipsychotic 
drugs class (DDD/1000 inhabitants/day).
Figure 4. Consumption of  typical and atypical antipsychotics in different regions and at the na-
tional level (DDD/1000 inhabitants/day). At a national level (p = 0,0004; strength (with significance 
level ≤ 0,05) = 98,7%; correlation coefficient is statistically significant). 
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Discussion
Figure 1 shows clearly that the morbid-
ity and consumption of  antipsychotics have 
the same increasing trend, but from 2005 and 
onwards it is evident that a non-minor frac-
tion of  the psychotic patients are not treated 
within the scheme. The non-compliance in 
the relationship morbidity – treatment under 
the scheme becomes again evident. 
Attempting to obtain a deeper under-
standing of  what has really happened and 
taking into consideration the specifics of  the 
new generation of  antipsychotic drugs – that 
are expensive ones – we included in the anal-
ysis the import data (which represent the real 
consumption), by comparing the average an-
nual value of  consumption of  antipsychotic 
drugs from imports with the equivalent value 
reported by the HII.
Figure 2 presents the comparison import-
HII in the consumption of  some atypical an-
tipsychotics, which factually are the only ones 
included in the reimbursement scheme. We 
note that around 20-30% of  the consump-
tion flows out of  the scheme. Meanwhile, in 
the domestic pharmaceutical market circulate 
other new antipsychotics, consumed out of  
the scheme, such as piperazine, quetiapine, 
sulpiride.
A possible reason of  this flow out of  the 
scheme may be the fact that the scheme does 
not sufficiently cover the indispensable al-
ternatives of  treatment of  psychotic disor-
ders. Another noticeable fact is that, accord-
ing to HII’s protocol, the maintenance dose 
for olanzapine is recommended at 5 mg/day, 
whereas the international therapeutic guide-
lines recommend daily maintenance dose of  
5 to 20 mg in one taking or split between a 
Figure 5. International comparison in the consumption of  anti-psychotic drugs class (DDD/1000 
inhabitants/day): Albania, Estonia [12-14], Norway [15-17], Finland [18-20].
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few meals. HII recommends maintenance 
dose for risperidone of  3 mg/day, whereas 
the international therapeutic guidelines rec-
ommend a daily maintenance dose of  3 to 
5 mg [21]. Hence, it can be clearly noted the 
propensity to a therapeutic treatment with di-
minished doses, which can result deficient.
On the other hand, based on HII’s proto-
col, the prescription of  the new generation 
of  antipsychotics (atypical) should be limited 
only to cases of  schizophrenia resistant to 
classic antipsychotics. In these circumstanc-
es, obtaining these drugs through the scheme 
becomes difficult. In Figure 3, the difference 
imports-HII is even more evident, conclud-
ing that only 40% of  the consumption of  an-
tipsychotics is covered by the scheme. 
With the launch in the market of  the new 
generation of  antipsychotics (atypical) in the 
mid 90’s, this new group has widely substi-
tuted antipsychotics of  the first generation 
(classic) as a chosen therapy for disorders of  
psychotic nature [22]. These drugs are char-
acterized by a higher security profile and their 
broad use has reduced significantly the need 
for hospitalization of  psychotic patients [23]. 
The consumption of  antipsychotic drugs 
is subject to changes and refractions from 
year to year in nearly all regions (Figure 4), 
a result not consistent with the natural in-
creasing trend of  psychotic morbidity. The 
minimum consumption is noted in Kukës 
throughout all years under study. High values 
of  consumption for this class are noted in 
Tiranë, Vlorë, Korçë since in 2004. In 2006, 
there is a reduction of  consumption for all 
regions, and subsequently a gradual increase. 
The fact that this occurrence in 2006 is re-
flected in the majority of  classes, it can be 
related to the increase of  restrictions in pre-
scription determined by HII.
Vlora region draws particular attention 
due to the high consumption values (it is 
the region with the maximum consumption 
values for the class in years 2007 and 2009). 
This occurrence may be explained with the 
presence in this region of  a psychotic service 
center with a long experience. It needs to be 
emphasized though that this is the only class 
of  drugs that achieves high consumption val-
ues in Vlora, a region that as outlined above, 
is characterized by a low consumption of  all 
other therapeutic classes.
At the national level, the consumption 
of  antipsychotic drugs undergoes a dis-
crete increase of  36.94% (from 2.19 to 3.49 
DDD/1000 inhabitants/day during the pe-
riod 2004-2016), which is lower than the in-
crease that would be expected based on the 
data on psychotic morbidity during the same 
period which show an increase of  96.05%, 
almost the double (from 2.07 to 5.79 cas-
es/1000 inhabitants). 
In the list for this class dominate typical 
antipsychotics as compared to atypical anti-
psychotics (the new generation), including 
clozapine, olanzapine and risperidone. It can 
be noted a non-consistency in the trend of  
consumption of  these two antipsychotic gen-
erations: there is only a small increase in the 
consumption of  typical (old) antipsychotics 
of  6.01% (from 1.60 to 1.70 DDD/1000 in-
habitants/day, 2004-2016) while there is an 
evident increase of  the consumption of  the 
new generation from 0.59 to 1.79 DDD/1000 
inhabitants/day, 2004-2016). 
This movement in consumption towards 
atypical antipsychotics is clearly reflected also 
in the prescription trends (DDD%) for each 
antipsychotic alternative.
A decrease can be noted, in certain cases 
even drastic, in the prescription of  old anti-
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psychotics. As such, the prescription of  halo-
peridol falls from 22.43% to 14.11% during 
the period 2004-2016. Furthermore, thio-
ridazine, fluphenazine, chlorpromazine have 
been prescribed 2-3 times less during this pe-
riod. On the other hand, there is a burst of  
prescriptions of  the new generation: e.g. the 
prescription of  olanzapine increased from 
4.07% to 18.10%; of  clozapine from 7.20% 
to 11.77%.
This polarization in the consumption of  
antipsychotics is a phenomenon observed 
in many countries. During the last decade, 
the therapeutic treatment of  schizophrenia 
and psychotic syndromes has been subject 
to changes with the launch in the market of  
atypical antipsychotics (generation II). In dif-
ferent international therapeutic guidelines, 
the new antipsychotics are considered as the 
first therapeutic choice in the treatment of  
schizophrenia, taking into account that these 
drugs offer a more favorable security profile 
as compared to old antipsychotics [24,25].
Several studies have reported that the use 
of  the new generation is accompanied with a 
notable reduction in the appearance of  extra-
pyramidal side effects, although on the hand, 
there is an increasing concern related with 
side effects in the metabolic sphere, includ-
ing diabetes, dyslipidemia and obesity [26,27].
Other studies demonstrate that atypical 
antipsychotics have higher efficacy in the pre-
vention of  re-occurrence of  psychotic crisis, 
very low risk of  extrapyramidal effects and 
superior adherence of  patients to the thera-
py. However, the debate on the cost-efficacy 
ratio of  these drugs in ongoing one [28,29]. 
From this perspective, regardless of  their 
high direct cost, these drugs offer a more fa-
vorable long term cost-efficacy ratio, since 
they reduce significantly the suffering that 
this pathology causes to the individual, his 
family, the society, as well as the economic 
cost related to the hospitalization of  patients.
While sketching international compari-
sons (Figure 5), a common feature for all 
countries is the movement in prescription 
and consumption towards the new genera-
tion, accompanied by a decrease in consump-
tion of  classic antipsychotics. Regarding the 
values of  such consumption, we may again 
conclude that in Albania, these drugs are 
consumed a few times less as compared to 
the majority of  other countries, leaving room 
to assume that there is maybe an under-diag-
nosis and under-treatment of  psychotic dis-
orders in our country. 
Many factors might influence this fact; 
with the main finding that suggest a much 
lower consumption of  antipsychotics in 
comparisons with other countries. Authors 
have performed comparisons with northern 
European countries and found significant 
changes; although the trend of  consumption 
has increased recently, figures are still below 
average values. This might be true even when 
comparisons are made within neighboring 
countries. Worth mentioning as well is the 
impressive decrease in the consumption of  
old-generation antipsychotics in favor of  the 
atypical ones. The ever-changing drug mar-
ket the availability of  some new principles 
that are used off-label or unregistered, and 
the flow of  surrogate medications out from 
the reimbursement scheme represent some 
of  the limitations of  the findings disclosed in 
the present study. The demographic changes 
might have also their say in the overall con-
sumption data, as long as newly approved 
drug indications will enlarge the scope of  use 
of  antipsychotics in an ageing population, es-
pecially for people with dementia [30].
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Conclusions
Different particularities in the overall 
out-of-hospital antipsychotics consumption 
inside Albania are found during the period 
of  study (2004-2016). Of  interest would be 
the extension of  this study among in-patient 
consumers, i.e. inside hospital facilities, where 
until recently the pharmacological treatment 
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Potrošnja antipsihotika u primarnoj zdravstvenoj zaštiti u 
Albaniji od 2004. do 2016. godine
Sažetak - Razdoblje novih antipsihotika koje je započelo s klozapinom i sve većim brojem novopatentira-
nih lijekova snažno je utjecalo na obrazac uporabe i korištenja lijekova u psihijatrijskih pacijenata. Istraživači 
predstavljaju istraživanje čiji je cilj procijeniti isključivo izvanbolničku potrošnju antipsihotika u Albaniji u raz-
doblju od trinaest godina (2004-2016). Podaci su dobiveni iz službenih izvora (Zavoda za zdravstveno osigu-
ranje) koji registriraju i u konačnici pokrivaju trošak svih propisanih lijekove u ovome području. Objavljeni 
su i određeni odljevi iz sustava službene nadoknade troškova, a zbog korištenja novih (no ne i registriranih) 
lijekova. Primijećen je značajan trend smanjenja potrošnje starih, tipičnih antipsihotika; u korist novijih i mod-
ernijih lijekova čiji je profil nuspojava očigledno bolji. U usporedbi s drugim državama, Albanija ima niže brojke 
ukupnog izvanbolničkog korištenja antipsihotika. Nedovoljno dijagnosticiranje i liječenje mogli bi biti neki od 
čimbenika koji objašnjavaju takvo stanje, zajedno s pristupačnošću psihijatrijske skrbi i društvenom stigmom 
koja je i danas duboko ukorijenjena u albansko društvo.
Ključne riječi: antipsihotici, vanbolnička njega, psihoza, morbiditet, atipični antipsihotici
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